Cargando…

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

IMPORTANCE: The BNT162b2 vaccine showed high efficacy against COVID-19 in a phase III randomized clinical trial. A vaccine effectiveness evaluation in a real-world setting is needed. OBJECTIVE: To assess the short-term effectiveness of the first dose of the BNT162b2-vaccine against SARS-CoV-2 infect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chodick, Gabriel, Tene, Lilac, Patalon, Tal, Gazit, Sivan, Ben Tov, Amir, Cohen, Dani, Muhsen, Khitam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185600/ https://www.ncbi.nlm.nih.gov/pubmed/34097044 http://dx.doi.org/10.1001/jamanetworkopen.2021.15985

Ejemplares similares

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2023)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
por: Gazit, Sivan, et al.
Publicado: (2023)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2021)

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
por: Prunas, Ottavia, et al.
Publicado: (2021)

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
por: Prunas, Ottavia, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Dynamics in COVID-19 symptoms during different waves of the pandemic among children infected with SARS-CoV-2 in the ambulatory setting
por: Ben-Tov, Amir, et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
por: Mizrahi, Barak, et al.
Publicado: (2021)

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
por: Gazit, Sivan, et al.
Publicado: (2022)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Evaluating red blood cell distribution width from community blood tests as a predictor of hospitalization and mortality in adults with SARS-CoV-2: a cohort study
por: Banon, Tamar, et al.
Publicado: (2021)

Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study
por: Fallach, Noga, et al.
Publicado: (2022)

Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data
por: Tene, Lilac, et al.
Publicado: (2023)

Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents
por: Patalon, Tal, et al.
Publicado: (2023)

Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021
por: Muhsen, Khitam, et al.
Publicado: (2022)

SARS-CoV-2 RT-qPCR Test Detection Rates Are Associated with Patient Age, Sex, and Time since Diagnosis
por: Levine-Tiefenbrun, Matan, et al.
Publicado: (2022)

An Outbreak of Parvovirus B19 in Israel
por: Patalon, Tal, et al.
Publicado: (2023)

Immunosuppression as a Hub for SARS-CoV-2 Mutational Drift
por: Shapira, Guy, et al.
Publicado: (2023)

Waning of SARS-CoV-2 booster viral-load reduction effectiveness
por: Levine-Tiefenbrun, Matan, et al.
Publicado: (2022)

Physicians’ adherence to management guidelines for H. pylori infection and gastroesophageal reflux disease: a cross-sectional study
por: Na’amnih, Wasef, et al.
Publicado: (2020)

A survey of primary-care pediatricians regarding the management of Helicobacter pylori infection and celiac disease
por: Ben Tov, Amir, et al.
Publicado: (2019)

A Data-Driven Strategy for Identifying Individuals Resistant to SARS-CoV-2 Virus under In-Household Exposure
por: Hen Gabzi, Roni, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study
por: Layan, Maylis, et al.
Publicado: (2022)

79. Long-term Health Outcomes of Individuals who are Infected with SARS-CoV-2 and Develop COVID-19
por: Tene, Lilac, et al.
Publicado: (2022)

Helicobacter pylori Infection and Anemia
por: Muhsen, Khitam, et al.
Publicado: (2013)

Vaccines for enteric diseases
por: Cohen, Dani, et al.
Publicado: (2019)

COVID-19 vaccination in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Transplacental transfer of SARS-CoV-2 antibodies in recovered and BNT162b2-vaccinated patients
por: Treger, Sharon, et al.
Publicado: (2022)

Correlates of gastroenterology health-services utilization among patients with gastroesophageal reflux disease: a large database analysis
por: Na’amnih, Wasef, et al.
Publicado: (2019)

P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
por: Tadmor, Tamar, et al.
Publicado: (2023)

A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020–February 2021
por: Muhsen, Khitam, et al.
Publicado: (2021)

Mpox Patient Journey in Israel
por: Patalon, Tal, et al.
Publicado: (2023)

Mpox Infection in a Developed Country: A Case Report
por: Patalon, Tal, et al.
Publicado: (2022)

SARS-CoV-2 spike IgG titres up to 137 days following Comirnaty mRNA COVID-19 vaccination, Israel, February to May 2021
por: Patalon, Tal, et al.
Publicado: (2022)

Pregnancy Course of 10 Women Diagnosed with Chronic Lymphocytic Leukemia
por: Tadmor, Tamar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mi9govmpeol3qemfae120v8bb1